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IMPORTANCE Both hydrocortisone and pasireotide have been shown in randomized clinical
trials to be effective in reducing postoperative complications of pancreatic surgery, but to
date no randomized clinical trial has evaluated the effectiveness of pasireotide compared
with hydrocortisone.
OBJECTIVE To assess the noninferiority of hydrocortisone compared with pasireotide in
reducing complications after partial pancreatectomy.
DESIGN, SETTING, AND PARTICIPANTS A noninferiority, parallel-group, individually randomized
clinical trial was conducted at a single academic center betweenMay 19, 2016, and December
17, 2018. Outcome collectors and analyzers were blinded. A total of 281 patients undergoing
partial pancreatectomywere assessed for inclusion. Patients younger than 18 years, those
allergic to hydrocortisone or pasireotide, patients undergoing pancreaticoduodenectomy
with hard pancreas or dilated pancreatic duct, and patients not eventually undergoing partial
pancreatectomywere excluded. Modified intention-to-treat analysis was used in
determination of the results.
INTERVENTIONS Treatment included pasireotide, 900 μg, subcutaneously twice a day for
7 days or hydrocortisone, 100mg, intravenously 3 times a day for 3 days.
MAIN OUTCOMES ANDMEASURES The primary outcomewas the Comprehensive Complication
Index (CCI) score within 30 days. The noninferiority limit was set to 9 CCI points.
RESULTS Of the 281 patients (mean [SD] age, 63.8 years) assessed for eligibility, 168 patients
(mean [SD] age, 63.6 years) were randomized and 126 were included in themodified
intention-to-treat analyses. Sixty-three patients received pasireotide (35men [56%]; median
[interquartile range] age, 64 [56-70] years) and 63 patients received hydrocortisone (25men
[40%]; median [interquartile range] age, 67 [56-73] years). Themean (SD) CCI score was
23.94 (17.06) in the pasireotide group and 30.11 (20.47) in the hydrocortisone group (mean
difference, –6.16; 2-sided 90%CI, –11.73 to –0.60), indicating that hydrocortisone was not
noninferior. Postoperative pancreatic fistula was detected in 34 patients (54%) in the
pasireotide group and 39 patients (62%) in the hydrocortisone group (odds ratio, 1.39; 95%
CI, 0.68-2.82; P = .37). One patient in the pasireotide group and 2 patients in the
hydrocortisone group died within 30 days. In subgroup analyses of patients undergoing distal
pancreatectomy, the CCI score was a mean of 10.3 points lower (mean [SD], 16.03 [11.94] vs
26.28 [21.76]; 2-sided 95% CI, −19.34 to −2.12; P = .03) and postoperative pancreatic fistula
rate was lower (37% vs 67%; P = .02) in the pasireotide group compared with the
hydrocortisone group.
CONCLUSIONS AND RELEVANCE In this study, hydrocortisonewas not noninferior compared
with pasireotide in patients undergoing partial pancreatectomy. Pasireotide may bemore
effective than hydrocortisone in patients undergoing distal pancreatectomy.
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P ancreatic surgery carries a high risk for complica-tions, and pancreatic fistula remains the main causeof most of the serious complications. Several meth-
ods have been introduced during the past decades to
address the problem and reduce the incidence of pancreatic
fistula and overall complication burden after pancreatic sur-
gery. For pancreaticoduodenectomy, these methods include
different types of pancreaticoenteric anastomoses, different
drainage strategies, and various stenting methods of the
pancreatic duct.1-4 For distal pancreatectomies, different
cutting methods and pancreatic stump sealing strategies
have been used.5,6 Somatostatin analogs, especially octreo-
tide, have also been used for both pancreaticoduodenec-
tomy and distal pancreatectomy. Although the use of
octreotide is widespread in some countries, octreotide has
not gained full acceptance globally, as meta-analyses have
not shown consistent benefit.7,8 Despite rigorous research,
postoperative pancreatic fistula remains a significant chal-
lenge: up to every third patient at high risk will develop a
clinically significant pancreatic fistula.6,9
Pasireotide is a somatostatin analog with high affinity to
4 of the 5 somatostatin receptors, while octreotide binds
only to 2 somatostatin receptors with high affinity.10 On this
theoretical basis, it can be hypothesized that pasireotide
could be more effective in preventing postoperative pancre-
atic fistula. Clinical proof of this efficacy has been obtained
from 1 randomized clinical trial in which pasireotide halved
the rate of pancreatic fistula in patients undergoing pancre-
aticoduodenectomy or distal pancreatectomy.11 Although
the association between pasireotide and reductions in the
incidence of pancreatic fistula has been challenged by sev-
eral nonrandomized studies or retrospective series,12-14 to
our knowledge, no other prospective randomized clinical
trial evaluating the effectiveness of pasireotide exists.
Another pharmacologic strategy to mitigate the rate of
postoperative pancreatic fistula is perioperative hydrocorti-
sone treatment. Randomized clinical trials compared hydro-
cortisone with placebo in patients at high risk for pancreatic
fistula undergoing pancreaticoduodenectomy or distal pan-
createctomy and showed that hydrocortisone reduces major
complications after pancreaticoduodenectomyand the rateof
postoperativepancreatic fistulaafterdistalpancreatectomy.15,16
Althoughthestudycohortsof these2 randomizedclinical trials
were not comparable, hydrocortisone seemed to be similarly
effective in reducing pancreatic surgery complications com-
pared with pasireotide.
Toevaluate thebestpharmacologic therapyto reducepost-
operative complications for patients undergoing partial pan-
createctomy,weconducted theHydrocortisonevsPasireotide
in Reducing Pancreatic Surgery Complications (HYPAR) trial.
Because pasireotide is substantiallymore expensive than hy-
drocortisone and earlier trials suggested equal effectiveness,
we aimed to show noninferiority of hydrocortisone in terms
of overall postoperative complications in patients undergo-
ing partial pancreatectomy with high risk of pancreatic fis-
tula. Patients undergoing pancreaticoduodenectomy with a
hard pancreas or dilated pancreatic ductwere not included in
the trial because their risk for pancreatic fistula is low.17
Methods
Study Design and Participants
The HYPAR trial was a single-center, prospective, parallel-
group, randomized, noninferiority trial comparingperiopera-
tivehydrocortisonewithpasireotide inpatients athigh risk for
pancreatic fistula and postoperative complications. The trial
was carried out in Helsinki University Hospital, Helsinki,
Finland, which is an academic teaching hospital and func-
tions both as a secondary (servedpopulation, 1.2million) and
tertiary referral (served population, 1.9 million) center.
The trial was approved by the Finnish National Commit-
tee on Medical Research Ethics, Finnish Medicines Agency,
Helsinki University Hospital’s ethical committee, and the
Helsinki University Hospital Institutional Review Board. All
randomized patients gave written informed consent; no fi-
nancial compensationwas provided. This study followed the
Consolidated Standards of Reporting Trials (CONSORT)
reportingguideline for randomizedclinical trials. Theprotocol
is available in Supplement 1.
Patients scheduled for elective partial pancreatectomy
(pancreaticoduodenectomy, distal pancreatectomy, enucle-
ation, or other resection) were eligible for inclusion. Exclu-
sion criteriawere atrophic pancreas or dilatedpancreatic duct
(diameter of ≥4 mm) at the resection line in preoperative
imaging in patients undergoing pancreaticoduodenectomy,
planned total pancreatectomy, allergy or other contraindica-
tion for cortisoneor pasireotide, age younger than 18 years, or
nowritten informedconsent given.Randomization tookplace
before surgery, because the first dose of either hydrocorti-
sone or pasireotide was given before the patient was moved
to theoperating room.For this reason, additional exclusioncri-
teriawere set and checked intraoperatively. Patientswere ex-
cluded from the trial after randomization if no pancreatic re-
section took place (eg, disseminated cancer) or total
pancreatectomy was performed (ie, no risk of pancreatic fis-
tula). Furthermore, patients undergoing pancreaticoduode-
nectomy with a hard pancreas or dilated pancreatic duct are
at low risk for pancreatic fistula, and thuswere excluded from
Key Points
Question Is hydrocortisone noninferior compared with
pasireotide in reducing pancreatic surgery complications?
Findings In this randomized clinical trial that included
126 patients undergoing partial pancreatectomy, themean
Comprehensive Complication Index score (a measurement of
overall postoperative morbidity) was –6.16 points lower in patients
receiving pasireotide and the lower limit of the 90%CI crossed the
prespecified noninferiority margin (–9). In subgroup analyses of
patients undergoing distal pancreatectomy, themean
Comprehensive Complication Index score was significantly lower
(10.3 points) in the pasireotide vs hydrocortisone group.
Meaning In this study, hydrocortisone is not noninferior
compared with pasireotide, and pasireotide may bemore effective
in reducing postoperative complications in patients undergoing
distal pancreatectomy.
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the trial. In other types of resection (enucleation, distal pan-
createctomy), patients were not excluded based on their
pancreas type during surgery.
Randomization and Blinding
Patients were randomly allocated 1:1 to receive either peri-
operative hydrocortisone or pasireotide treatment. The ran-
domization sequence was generated using a computer algo-
rithm with randomly variable block size (2, 4, and 6). The
randomization sequence was concealed in opaque and num-
bered envelopes. The recruiters, treating physician, operat-
ingsurgeon, researchers, andpatientswereunawareof the ran-
domization sequence. Patients were randomized by a study
nurse by opening the sealed envelope containing the alloca-
tion group. The allocated group was concealed from treating
physicians, surgeons, researchers,outcomeassessors,datacol-
lectors, and data analysts until all of the data were collected.
The groupswere then labeled as 1 and 2, and the primary and
secondary end points were analyzed without the knowledge
of which group was which. Possible incidents of failed blind-
ing were recorded.
Intervention
Patients allocated to the pasireotide group received pasire-
otide, 900 μg, twice a day subcutaneously, starting on the
morningof theoperationandcontinuinguntil theeveningdose
on postoperative day 6 (14 doses) or until discharge if earlier.
Patients allocated to the hydrocortisone group received hy-
drocortisone, 100mg, intravenously 3 times aday, starting on
the morning of the operation and continuing until the eve-
ning dose on postoperative day 2 (9 doses). Patients in both
groups were otherwise treated similarly according to the
Enhanced Recovery After Surgery protocol.18 For pancreati-
coduodenectomy,pancreaticojejunostomywasformedinduct-
to-mucosa fashion with 4-0 or 5-0 polydioxanone sutures in
2 layers, and 2 closed passive drains were inserted in the ab-
dominal cavity next to the hepaticojejunostomy and pancre-
aticojejunostomy. All pancreaticoduodenectomies were per-
formed open. For distal pancreatectomy, the pancreas was
dividedusing a linear stapler or, in cases of thickpancreas, the
division was performed using a cold knife and the resection
line was sutured. Distal pancreatectomies were performed
open, laparoscopic, or robot-assisted.Oneclosedpassivedrain
was left next to the pancreas stump after distal pancreatec-
tomy. For both pancreaticoduodenectomies and distal pan-
createctomies, the drains were left in place for at least up to
postoperative day 3. Amylase levels weremeasured from the
drain output and, if the levels were high, the drains were left
in place longer than usual.
Outcomes
The primary outcome of the trial was the Comprehensive
Complication Index (CCI) score within 30 days after the op-
eration. The CCI takes into account all cumulative complica-
tions and receives values between 0 and 100. A 10-point dif-
ference reflects a 1-gradedifference in theestablishedClavien-
Dindo classification.19 Secondary outcomes included
complications graded by Clavien-Dindo classification,
postoperativepancreatic fistula rate (InternationalStudyGroup
ofPancreatic Surgery [ISGPS] classification), postoperativede-
layedgastric emptying rate (ISGPS classification), postpancre-
atectomy hemorrhage (ISGPS classification), and readmis-
sions, all within 30 days after the operation, and length of
hospital stay assessed at discharge.20-24 Outcome measures
were assessedduring thehospital stay andat outpatient clinic
visits or by phone call 30 days after surgery. Other outcome
measures included rate of adjuvant therapy within 6months
after surgery in patients with histologically verified cancer.
Overall, disease-specific and disease-free survival will be as-
sessed and reported when 5- and 10-year follow-up data are
available.
Statistical Analysis
We chose the CCI as the primary outcome because it is based
on the established Clavien-Dindo classification system but
takes into account all cumulative complications and is thus
more sensitive indicator of overall complication burden. We
set the noninferiority limit at 9 points, because a 10-point dif-
ference reflects 1 Clavien-Dindo grade difference in compli-
cation burden.19 We aimed to show that the CCI score in the
hydrocortisone groupwouldnot bemore than9points higher
than the score in the pasireotide group. Based on published
data,weassumed theSD tobe20.19Wecalculated that 124pa-
tients were needed to show noninferiority of hydrocortisone
with 80% power and a 1-sided α level of .05.
Noninferioritywas testedby the lower limit of the 90%CI
of the mean difference (equivalent of the 95% CI of a 1-sided
test). If the lower limit of the CCI mean difference 90% CI is
lower than –9, noninferiority is notmet. The primary CCI and
secondary lengthof stayoutcomesarepresentedasmean (SD)
and comparedbetweengroupsusing independent t testswith
bootstrapping.Only theprimary outcomewas assessedusing
noninferiority testing; the secondary outcomes were as-
sessed using the superiority approach. Categorical secondary
outcomemeasureswere comparedusing a χ2 test. Effect sizes
are reported either asmean differencewith 95%CI or odd ra-
tios (ORs) with 95% CI. All P values reported are 2-sided and,
for superiority testing, P < .05 was considered statistically
significant. Datawere reported asmissing, if necessary, in the
tables or in text for each variable. Missing data were omitted
from analyses of the particular variable in question and no
missingdatawere imputed.All outcomeswere analyzedusing
modified intention-to-treat analyses, where all randomized
patients inwhom the study drugwas continued after surgery
were included in the analyses. Prespecified subgroup analy-
ses were performed using superiority testing for patients un-
dergoing pancreaticoduodenectomy or distal pancreatec-
tomy. Safety interim analysis was planned when 62 patients
were randomized.
Results
A total 281 patients were assessed for eligibility, of whom
168 patients were randomized to either perioperative hydro-
cortisone or pasireotide treatment between May 19, 2016,
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and December 17, 2018 (Figure). At surgery, a further 42
patients were excluded from the study, 25 because no pan-
creatic resection took place, 14 because the pancreas was
deemed to be low risk (hard pancreas or dilated pancreatic
duct), 1 because of concomitant use of somatostatin
analogs, and 2 because of logistic reasons. A total of 126
patients were included in the modified intention-to-treat
analyses (Figure). Baseline and operative characteristics
were similar between the groups (Table 1 and Table 2). In
the whole study cohort the median age of the patients was
66 years, 63 patients (50%) were American Society of Anes-
thesiologists class 3 or 4, and median Charlson Comorbidity
Index score was 2. In the pasireotide vs hydrocortisone
group, 35 patients (56%) vs 25 patients (40%) were men,
median (interquartile range) age was 64 (56-70) vs 67
(56-73) years, mean (SD) body mass index (calculated as
weight in kilograms divided by height in meters squared)
was 27.3 (3.6) vs 26.8 (4.3), 31 (49%) vs 32 (51%) patients
were American Association of Anesthesiologists class 3 or 4,
and preoperative biliary drainage was performed in 21 (33%)
vs 15 (24%) patients. Only 2 patients per group underwent
neoadjuvant therapy. Fistula risk scores25 indicated that
patients undergoing pancreaticoduodenectomy in the trial
had, on average, intermediate risk for postoperative pancre-
atic fistula (Table 2). Blinding was reported to have failed in
4 patients (1 unintentionally in both groups with the drug
identified for treating physicians, 1 deliberately in the
hydrocortisone group by the treating physicians who
stopped the drug because of severe nausea, and 1 uninten-
tionally in the hydrocortisone group with the drug identi-
fied for data collectors). The drug was prematurely stopped
in 7 patients (6 patients in the pasireotide group: 5 for nau-
sea, 1 for suspected allergic reaction at a median of 2 days
after the operation, and 1 patient in the hydrocortisone
Figure. FlowDiagram of Patient Recruitment and Randomization
281 Patients assessed for eligibility
168 Randomized
113 Excluded
87 Had atrofic pancreas or
dilated duct on
preoperative CT
2 Used high-dose cortisone
4 Declined to participate
8 Used somatostatin analogs
4 Were scheduled for a total
pancreatectomy
3 Were planned to have
simultaneous liver resection
2 Had contraindication for
either of the study drugs
3 Had an emergency surgery
84 Randomized to pasireotide
21 Discontinued study owing
to ineligibility
12 Did not undergo
a pancreatic resection
6 Were found to have firm
pancreas and/or dilated
duct during resection
1 Was randomized despite
use of somatostatin
analogs
2 Did not receive drug after
surgery owing to logistic
errors
63 Included in primary analysis
84 Randomized to hydrocortisone
21 Discontinued study owing
to ineligibility
13 Did not undergo
a pancreatic resection
8 Were found to have firm
pancreas and/or dilated
duct during resection
63 Included in primary analysis
CT indicates computed tomography.
Table 1. Baseline Characteristicsa
Characteristic
No. (%)
Pasireotide
(n = 63)
Hydrocortisone
(n = 63)
Age, median (IQR), y 64 (56-70) 67 (56-73)
Sex, male 35 (56) 25 (40)
BMI, mean (SD) 27.3 (3.6) 26.8 (4.3)
ASA physical status
1 2 (3) 2 (3)
2 30 (48) 29 (46)
3 29 (46) 29 (46)
4 2 (3) 3 (5)
Charlson Comorbidity Index diseases
Coronary disease/myocardial
infarction
5 (8) 2 (3)
Congestive heart failure 2 (3) 1 (2)
Hypertension 30 (48) 26 (41)
Peripheral vascular disease 3 (5) 3 (5)
Cerebrovascular disease 1 (2) 2 (3)
Hemiplegia 0 0
Dementia 0 1 (2)
COPD or asthma 12 (19) 9 (14)
Connective tissue disease 2 (3) 4 (6)
Liver disease 1 (2) 0
Mild 1 (2) 0
Moderate or severe 0 0
Diabetes 11 (18) 10 (16)
Without complications 11 (18) 10 (16)
With complications 0 0
Kidney disease, moderate or severe 0 1 (2)
Cancer 42 (67) 48 (76)
Local 40 (64) 43 (68)
Metastatic 2 (3) 5 (8)
Leukemia 0 0
Lymphoma 0 0
No comorbidities 7 (11) 11 (18)
Charlson Comorbidity Index category,
No. (%)
Mild (0-2) 45 (71) 37 (59)
Moderate (3-4) 15 (24) 18 (29)
Severe (≥5) 3 (5) 8 (13)
Charlson Comorbidity Index score,
mean (SD)
2.0 (1.4) 2.4 (1.9)
Abbreviations: ASA, American Association of Anesthesiologists; BMI, bodymass
index (calculated as weight in kilograms divided by height in meters squared);
COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
a No significant differences were identified between the treatment groups in
any baseline variables.
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group on the second postoperative day for nausea). For dis-
tal pancreatectomy, the pancreatic stump was closed in the
pasireotide vs hydrocortisone groups with a stapler in 14
(47%) vs 19 (63%) patients, enforced stapler in 14 (47%) vs 11
(37%) patients, and suturing in 2 (7%) vs 0 patients.
The mean (SD) CCI score was 23.94 (17.06) in the pasire-
otide group and 30.11 (20.47) in the hydrocortisone group
(mean difference, –6.16; 2-sided 95% CI, –12.81 to 0.48;
2-sided 90% CI, –11.73 to –0.60). The lower limit of the 90%
CI crossed the prespecified –9 noninferiority limit, indicat-
ing that hydrocortisone was not noninferior (Table 3). Pan-
creatic fistula rate and other secondary outcomes were simi-
lar between the groups, except that postpancreatectomy
hemorrhage was more frequent in the hydrocortisone vs
pasireotide group (7 [11%] vs 0; P = .01) (Table 3). Details of
other complications are reported in eTable 1 in Supple-
ment 2. Patients in the pasireotide group had higher glucose
levels and required more insulin and more antinausea medi-
cation during their hospital stay than patients in the hydro-
cortisone group (Table 4). One patient in the pasireotide
group and 2 patients in the hydrocortisone group died
within 30 days after the operation. The patient in the pasire-
otide group was a 79-year-old man with American Society of
Anesthesiologists class 3 and Charlson Comorbidity Index
score of 2. He underwent a pancreaticoduodenectomy for a
duodenal carcinoma. He had an ISGPS grade C postopera-
tive pancreatic fistula (ie, requires reoperation), which
resulted in septic shock and relaparotomy on postoperative
day 14. The pancreaticojejunal anastomosis was resutured
and drained, but the patient developed multiorgan failure
and died on postoperative day 29. Autopsy verified that the
cause of death was postoperative pancreatic fistula. The
first patient who died in the hydrocortisone group was a
73-year-old man with American Society of Anesthesiologists
class 4 and a Charlson Comorbidity Index score of 9. He
underwent a pancreaticoduodenectomy for intraductal pap-
illary mucinous neoplasia with worrisome features, indicat-
ing risk of malignancy. He had an ISGLS grade C bile leakage
leading to a relaparotomy and rehepaticojejunostomy on
postoperative day 3. He died of massive aspiration due to
delayed gastric emptying on postoperative day 9, which was
verified in autopsy. The second patient who died in the
hydrocortisone group was a 73-year-old man with American
Society of Anesthesiologists class 3 and Charlson Comorbid-
ity Index score of 3. He underwent a distal pancreatectomy
for pancreatic cancer. He developed multiorgan failure on
postoperative day 6, was transferred to the intensive care
unit, and died on postoperative day 7. Autopsy verified that
the cause of death was a massive myocardial infarction
leading to multiorgan failure.
In subgroup analysis of patients undergoing pancreatico-
duodenectomy, the CCI score was 32.39 in the pasireotide
group vs 37.90 in the hydrocortisone group (mean
difference, –5.5; 95% CI, −15.46 to 4.12; P = .28) (eTable 2 in
Supplement2). Inaddition, all secondaryoutcomeswere simi-
lar between the groups in patients undergoing pancreatico-
duodenectomy, except postpancreatectomy hemorrhage,
whichwasmore frequent in thehydrocortisonegroup (4 [15%]
Table 2. Operative Characteristics
Characteristic
No. (%)
Pasireotide
(n = 63)
Hydrocortisone
(n = 63)
Preoperative drainage of biliary tract
No biliary drainage 42 (67) 48 (76)
ERCP 21 (33) 15 (24)
Time from biliary drainage to operation,
median (IQR), d
60 (38-79) 69 (38-88)
Resection type
Pancreaticoduodenectomy 30 (48) 27 (43)
Distal pancreatectomy 30 (48) 30 (48)
Open distal pancreatectomy 8 (27) 4 (13)
Laparoscopic, distala 16 (53) 22 (73)
Laparoscopic, distal converteda 6 (20) 4 (13)
Otherb 3 (5) 6 (10)
Vascular resection
Venous 4 (6) 5 (8)
Arterial 0 1 (2)
Blood loss during operation,
mean (SD), mL
550 (545) 572 (757)
Pancreatic duct diameter,
mean (SD), mmc
2.7 (1.3) 2.7 (1.6)
Pathologic findings
Pancreatic ductal adenocarcinoma 14 (22) 13 (21)
Cholangiocarcinoma 4 (6) 5 (8)
Papilla adenocarcinoma 5 (8) 3 (5)
Duodenal adenocarcinoma 3 (5) 1 (2)
IPMN 5 (8) 7 (11)
MCN 4 (6) 4 (6)
PNET 10 (16) 17 (27)
SPN 4 (6) 0
Serous cystadenoma 1 (2) 3 (5)
Papilla adenoma 2 (3) 1 (2)
Dysplasia, excluding papilla 5 (8) 6 (10)
Metastasis of another carcinoma 2 (3) 2 (3)
Otherd 4 (6) 1 (2)
Neoadjuvant therapye
None 28 (93) 23 (92)
Gemcitabine plus cisplatin 2 (7) 0
Chemoradiotherapy 0 1 (4)
Carboplatin plus etoposide 0 1 (4)
Fistula Risk Score,25 mean (SD)c 6.2 (1.7) 6.4 (1.8)
Modified Fistula Risk Score,9 mean (SD)c 8.3 (1.1) 7.8 (1.4)
Updated Alternative Fistula Risk Score,17
mean (SD)c
29.3 (10.9) 27.3 (11.3)
Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; IPMN,
intraductal papillary mucinous neoplasia; IQR, interquartile range; MCN,
mucinous cystic neoplasia; PNET, pancreatic neuroendocrine tumor; SPN, solid
pseudopapillary neoplasm
a Included robot-assisted procedures.
b Three enucleations in the pasireotide group and 3 enucleations, 2 median
pancreatectomies, and 1 transduodenal papillectomy in the
hydrocortisone group.
c Only for patients undergoing pancreaticoduodenectomy.
dOne pancreatic cystadenocarcinoma, 1 poorly differentiated pancreatic cancer,
1 benign choledochal cyst, and 1 lymphoepithelial cyst in the pasireotide
group. One adenosquamous carcinoma of the pancreas in the
hydrocortisone group.
e Total number of cancer cases (used as denominator) was 30 in the pasireotide
group and 25 in the hydrocortisone group.
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vs 0;P = .04) (eTable 2 in Supplement 2). Details of complica-
tions inpatientsundergoingpancreaticoduodenectomyare re-
ported in eTable 3 in Supplement 2.
In subgroup analysis for patients undergoing distal pan-
creaticoduodenectomy, theCCI score for thepasireotidegroup
was, on average, 10.25 less than in the hydrocortisone group
(mean, 16.03vs26.28;meandifference, –10.25; 95%CI, −19.34
to–2.12;P = .03).Elevenpatients (37%) in thepasireotidegroup
and 20 patients (67%) in the hydrocortisone group devel-
oped a postoperative pancreatic fistula (OR, 3.455; 95% CI,
1.195-9.990; P = .02). Four patients (13%) in the pasireotide
group and6patients (20%) in thehydrocortisone grouphad a
clinically significant (classBorC)postoperativepancreatic fis-
tula (OR, 1.625; 95% CI, 0.408-6.469; P = .49) (eTable 4 in
Supplement 2). Major complications (Clavien-Dindo 3b or
higher) occurredmore frequently in thehydrocortisonegroup
than the pasireotide group (6 [20%] vs 0; OR, 0.444 (95% CI,
0.330-0.599;P = .02).Details of complications inpatients un-
dergoing distal pancreatectomy are reported in eTable 5 in
Supplement 2.
Table 3. Primary and Secondary Outcomes
Outcome
No. (%)
P Valuea Effect Size, OR (95% CI)Pasireotide (n = 63) Hydrocortisone (n = 63)
Primary outcome
Comprehensive Complication index score,
mean (SD)
23.94 (17.06) 30.11 (20.47) .07 –6.16 (–12.81 to 0.48)b
Secondary outcome
Complications, any CD class 54 (86) 60 (95) .07 3.33 (0.86-12.95)
Clinically significant complications,
CD class ≥2
43 (68) 44 (70) .85 1.08 (0.51-2.29)
Major complications, CD class ≥3 5 (8) 10 (16) .17 2.19 (0.70-6.82)
Pancreatic fistula
Any 34 (54) 39 (62) .37 1.39 (0.68-2.82)
ISGPS class B or Cc 13 (21) 14 (22) .83 1.10 (0.47-2. 58)
Delayed gastric emptying
Any 12 (19) 19 (30) .15 1.84 (0.80-4.20)
ISGPS class B or Cc 6 (10) 5 (8) .75 0.82 (0.24-2.84)
Postoperative hemorrhage
Any 0 7 (11) .01 NAd
ISGPS class B or Cc 0 6 (10) .01 NAd
Length of hospital stay, median (IQR), de 8.0 (7.0-13.0) 10 (6.0-13.5) .95 0.006f
Readmission 7 (11)g 10 (16) .46 1.48 (0.53-4.18)
Adjuvant therapy among patients with cancerh 20/26 (77) 17/24 (71) .62 0.73 (0.21-2.59)
Abbreviations: CD, Clavien-Dindo; IQR, interquartile range; ISGPS, International
Study Group of Pancreatic Surgery; NA, not applicable; OR, odds ratio.
a P values for superiority.
bMean difference (95% CI). Two-tailed 90%CI was –11.73 to –0.60, which is the
equivalent of a 1-sided 95% CI, and the lower limit of this 90% CI was used to
test the noninferiority margin.
c ISGPS classification.21-23
d Effect size could not be calculated owing to a 0 in 1 cell.
e In the pasireotide group, 1 patient died and, in the hydrocortisone group,
2 patients died during the initial hospital stay.
f Effect size was calculated as r=Z/Nwithout 95% CI.
g One patient’s data on possible readmissions in his local community hospital
were missing.
h Total number of cancer cases was 30 in the pasireotide group and 25 in the
hydrocortisone group. Data on possible adjuvant therapy weremissing for 4
patients in the pasireotide group and 1 patient in the hydrocortisone group
owing to their oncologic consultation at other institutions.
Table 4. Postoperative Characteristics
Characteristic Pasireotide (n = 63) Hydrocortisone (n = 63) P Value
Postoperative maximum drain amylase, median (IQR), U/L 367 (107-1217) 388 (99-1245) .85
Postoperative maximum serum glucose, median (IQR), mg/dL 203.6 (180.2-268.5) 182.0 (165.8-223.4) .02
Total use of rapid- or short-acting insulin during hospital stay, mean (SD), IUa 13.0 (28.2) 8.7 (23.8) .03
Use of antinausea medication during hospital stay, mean (SD), da 4.1 (4.3) 1.9 (4.3) <.001
Time to oral feeding, median (IQR), db 4 (3-7) 5 (3-9) >.99
Abbreviation: IQR, interquartile range.
SI unit conversion: To convert serum glucose tomillimoles per liter, multiply by
0.0555.
a Total use of insulin and antinauseamedication was reported as themean,
although the data were not normally distributed, because themedian was
0 in both groups.
bOne patient in the pasireotide group and 2 patients in the hydrocortisone
group died before proceeding to oral feeding. One patient in the
hydrocortisone group had a gastrostomy tube and never proceeded to oral
feeding.
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Discussion
The HYPAR trial compared use of perioperative hydrocorti-
sone with pasireotide in patients undergoing partial pancre-
atectomy and found that hydrocortisonewas not noninferior
comparedwithpasireotide inpatientsundergoingpartial pan-
createctomy. Both pasireotide and hydrocortisone have been
demonstrated to reduce complications of pancreatic
surgery,11,15,16 but, to our knowledge, they have not been pre-
viously comparedhead-to-head in a randomized clinical trial.
Patients in the pasireotide group had, on average, 6.16 fewer
CCIpoints thanpatients receivinghydrocortisone, but thisdif-
ferencedidnot reachstatistical significance. Insubgroupanaly-
ses for patients undergoing distal pancreatectomy,
pasireotidedecreasedoverall postoperativemorbidity signifi-
cantly andalsodecreasedpostoperativepancreatic fistula (pa-
sireotide: 11patients [37%];hydrocortisone:20patients [67%]),
but the study was not powered for subgroup analyses; thus,
these findings need to be addressed in another setting for
validation.
After the demonstration of superiority of pasireotide re-
ducing postoperative pancreatic fistula compared with pla-
cebo in a randomized clinical trial, several retrospective and
nonrandomized, prospective cohort studies have been pub-
lished. These nonrandomized studies were unable to exter-
nally verify the benefit of pasireotide in patients undergoing
pancreaticoduodenectomy13 or partial pancreatectomy.12,14
However, because they were not randomized, these studies
have various biases, which limit the confidence in their esti-
mates.Cost-effectivenessstudiesbasedontherandomizedtrial
suggested that theuse of pasireotide reduces the costs of care
by approximately $1100 to $1700.26,27 However, the cost of
1 dose of pasireotide is $273 in the United States,26 which is
more than 3-fold the cost in our center (€75 [US $84) and al-
most 5 times higher than in Germany (€52 [US $58]).28
Themechanism of action of pasireotide in reducing pan-
creatic fistula and, thus, overall complications, is considered
to take place via reduction of pancreatic secretion of diges-
tive enzymes and juice. Pasireotide has high affinity to 4 of 5
somatostatin receptors, while the more widely used soma-
tostatin analog octreotide only binds to 2 somatostatin recep-
tor typeswith high affinity.10 Theoretically, pasireotide could
bemoreeffective in termsof reducingpancreatic secretionand
postoperative pancreatic fistula, but head-to-head random-
ized clinical trials comparing pasireotide with octreotide are
lacking.Themechanismbywhichhydrocortisonereducespan-
creatic surgery complications is thought to be mediated
through its anti-inflammatory effects on reducingpostopera-
tive pancreatitis and pancreatic fistulas.15,29 However, evi-
dence fromanimal studies suggests that hydrocortisone also,
like somatostatin analogs, reduces pancreatic secretion.30,31
Given this theoreticalbackground,onemust recognize that the
exact mechanisms of somatostatin analogs and hydrocorti-
sone in reducing the rates of pancreatic fistula remain
unclear.
Limitations and Strengths
There are limitations in our study. First, this was a single-
center trial; amulticenter approachwouldhavegivenmoreex-
ternal validity to our estimates. Second, although we ob-
served fewer complications in the pasireotide group (mean
difference, 6.16 CCI points) and demonstrated that hydrocor-
tisone was not noninferior, we were unable to show inferior-
ity of hydrocortisone or superiority of pasireotide. This find-
ing might indicate a type 2 error (ie, false-negative finding
owingtoasmall samplesize).However, subgroupanalysessug-
gested that the benefits of pasireotide are more pronounced
inpatientsundergoingdistalpancreatectomy.Third, a3-armed
randomized clinical trial with a placebo armwould have pro-
videdmore strength to this study and a possibility to validate
previous findings against placebo. This approach is worth-
while to investigate in a future multicenter setting.
There are also strengths in our trial. First, new treat-
mentsshouldalwaysbecomparedwith thestandardor thebest
treatment available. To our knowledge, our trial is the first to
compare2pharmacologicpostoperativepancreatic fistulapro-
phylaxis agents head-to-head that have earlier been shown to
reduce pancreatic surgery complications compared with
placebo. Second, we used the CCI as the primary outcome,
which is the most sensitive method in classifying the overall
complicationburdenafter surgery. Third, patients included in
the trial were a median age of 66 years, 50% of them were
American Society of Anesthesiologists class 3 or 4, and the
median Charlson Comorbidity Index score was 2, indicating
that the trial cohort represents the case mix of real-life clini-
cal practice.
Conclusion
Our results suggest thathydrocortisone isnotnoninferior com-
pared with pasireotide in reducing complications in patients
undergoingpartial pancreatectomy.Pasireotide couldbemore
effective in reducingcomplications inpatientsundergoingdis-
tal pancreatectomy compared with hydrocortisone.
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